Structural capillary rarefaction and the onset of preeclampsia

Obstetrics and Gynecology

Volumn 119, Issue 5, 2012, Pages 967-974

  Nama, Vivek ^a,b,c,d   Manyonda, Isaac T ^a,b,c   Onwude, Joseph ^a,b,c   Antonios, Tarek F ^a,b,c  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Ramsay Springfield Hospital   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; CAPILLARY DENSITY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; GESTATIONAL AGE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUERPERIUM; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; CAPILLARIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MICROCIRCULATION; MICROSCOPY, VIDEO; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; SKIN;

EID: 84860205302     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31824ea092     Document Type: Article

References (31)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99. (Pubitemid 40311367)
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974.
3. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008; 118:968-76.
4. Hasan KM, Manyonda IT, Ng FS, Singer DR, Antonios TF. Skin capillary density changes in normal pregnancy and pre-eclampsia. J Hypertens 2002;20:2439-43. (Pubitemid 36026857)
5. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005. (Pubitemid 44343543)
6. Mourad JJ, Levy BI. Mechanisms of antiangiogenic-induced arterial hypertension. Curr Hypertens Rep 2011;13:289-93.
7. Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. January 2002. American College of Obstetrics and Gynecology. Obstet Gynecol 2002; 99:159-67.
8. Antonios TF, Rattray FE, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Maximization of skin capillaries during intravital video-microscopy in essential hypertension: comparison between venous congestion, reactive hyperaemia and core heat load tests. Clin Sci (Lond) 1999;97:523-8. (Pubitemid 29473753)
9. Antonios TFT, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Structural skin capillary rarefaction in essential hypertension. Hypertension 1999;33:998-1001. (Pubitemid 29186398)
10. Antonios TF, Kaski JC, Hasan KM, Brown SJ, Singer DR. Rarefaction of skin capillaries in patients with anginal chest pain and normal coronary arteriograms. Eur Heart J 2001;22: 1144-8. (Pubitemid 32666656)
11. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 2002;9:147-60. (Pubitemid 135685559)
12. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58. (Pubitemid 36278583)
13. Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000;4:441-58. (Pubitemid 30664037)
14. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972;1:177-91.
15. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H541-50. (Pubitemid 351253261)
16. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-7.
17. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004;145:4838-45. (Pubitemid 39551100)
18. Banks RE, Forbes MA, Searles J, Pappin D, Canas B, Rahman D, et al. Evidence for the existence of a novel pregnancyassociated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod 1998;4:377-86. (Pubitemid 28228534)
19. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998;59:1540-8. (Pubitemid 28549874)
20. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83. (Pubitemid 38364626)
21. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13. (Pubitemid 26272112)
22. Manyonda IT, Slater DM, Fenske C, Hole D, Choy MY, Wilson C. A role for noradrenaline in pre-eclampsia: towards a unifying hypothesis for the pathophysiology. Br J Obstet Gynaecol 1998;105:641-8. (Pubitemid 28293482)
23. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003;326:845.
24. Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension 2011;58:709-15.
25. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001;104:735-40. (Pubitemid 32738532)
26. Antonios TF, Rattray FM, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart 2003;89:175-8. (Pubitemid 36115101)
27. Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet 2001;357:53-6.
28. Antonios TFT, MacGregor GA. Generalized microvascular disease in essential hypertension: evidence from studies of cutaneous microcirculation. In: Levy BI, Struijker Boudier HA, editors. Role of micro and macrocirculation in target organ damage in diabetes and hypertension. Oxford (UK): Wiley-Blackwell; 2009. p. 54-67.
29. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-8. (Pubitemid 36056716)
30. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008;14:3470-6.
31. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011;58: 295-302.